Table 1.
Patient characteristics stratified by low-risk vs metastatic prostate cancer*
| Characteristic | Low-risk prostate cancer (N = 64 788), No. (%) | Metastatic prostate cancer (N = 8030), No. (%) |
| Age, y | ||
| 66–69 | 17 622 (27.2) | 1812 (22.6) |
| 70–74 | 22 224 (34.3) | 2248 (28.0 |
| 75–79 | 15 634 (24.1) | 1861 (23.2) |
| 80–84 | 6764 (10.4) | 1297 (16.2) |
| ≥85 | 2544 (3.9) | 812 (10.1) |
| Clinical tumor stage† | ||
| 1 | 46 333 (71.5) | 479 (6.0) |
| 2 | 18 455 (28.5) | 1295 (16.1) |
| 3 | 0 | 530 (6.6) |
| 4 | 0 | 5377 (67.0) |
| Unknown | 0 | 349 (4.3) |
| WHO grade‡ | ||
| 1 | 8564 (13.2) | 161 (2.0) |
| 2 | 56 224 (86.8) | 2590 (32.3) |
| 3 | 0 | 4298 (53.5) |
| Undifferentiated | 0 | 106 (1.3) |
| Unknown | 0 | 875 (10.9) |
| Charlson comorbidity index | ||
| 0 | 49 566 (76.5) | 6360 (79.2) |
| 1 | 10 391 (16.0) | 1079 (13.4) |
| 2 | 3060 (4.7) | 378 (4.7) |
| ≥3 | 1771 (2.7) | 213 (2.7) |
| Race | ||
| Non-Hispanic white | 51 578 (79.6) | 5932 (73.9) |
| Non-Hispanic black | 5253 (8.1) | 959 (11.9) |
| Hispanic | 5008 (7.7) | 608 (7.6) |
| Asian | 2719 (4.2) | 495 (6.2) |
| Other/unknown | 230 (0.4) | 36 (0.4) |
| Median income§ | ||
| 0–$35 654 | 15 033 (23.2) | 2290 (28.5) |
| $35 655–46 118 | 15 499 (23.9) | 2005 (25.0) |
| $46 119–60 409 | 15 630 (24.1) | 1866 (23.2) |
| ≥$60 410 | 16 003 (24.7) | 1499 (18.7) |
| Unknown | 2623 (4.0) | 370 (4.6) |
| Percent of adults with less than high school education§ | ||
| 0–18.5 | 15 755 (24.3) | 1712 (21.3) |
| 18.6–25.2 | 15 579 (24.0) | 1938 (24.1) |
| 25.3–32.5 | 15 420 (23.8) | 2013 (25.1) |
| 32.5–100 | 15 411 (23.8) | 1997 (24.9) |
| Unknown | 2623 (4.0) | 370 (4.6) |
| Rural status | ||
| Nonrural | 59 603 (92.0) | 7275 (90.6) |
| Rural | 5183 (8.0) | 755 (9.4) |
Includes patients reported by all SEER registries, including those added in 2000. As expected, there were statistically significant differences between the low-risk and metastatic groups in all clinical and demographic variables (ie, P < .001 for all comparisons, using two-sided χ2 test), so P values are not included in the table. SEER = Surveillance, Epidemiology, and End Results database; WHO = World Health Organization.
Clinical tumor stage from Clinical Extension variable in SEER.
WHO grade from SEER. WHO grade 1–2 correlates with Gleason score 2–7 tumors in 1992–2002 and Gleason score 2–6 tumors in 2003–2005.
Determined by average zip code level information according to 2000 United States census data.